Zimmer Biomet Sees Unusually Large Options Volume (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) was the target of some unusual options trading on Friday. Traders acquired 2,270 call options on the stock. This is an increase of 534% compared to the average daily volume of 358 call options.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ZBH shares. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Citigroup cut their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Monday. Stifel Nicolaus decreased their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, April 29th. Finally, Wells Fargo & Company lowered their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $102.33.

Zimmer Biomet Stock Performance

NYSE ZBH traded up $2.29 on Friday, hitting $91.52. 1,543,058 shares of the company’s stock were exchanged, compared to its average volume of 2,108,254. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm’s 50-day moving average price is $86.25 and its two-hundred day moving average price is $89.76. Zimmer Biomet has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The firm has a market cap of $17.70 billion, a price-to-earnings ratio of 23.77, a P/E/G ratio of 2.63 and a beta of 0.46.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the prior year, the business posted $1.81 EPS. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts expect that Zimmer Biomet will post 8.48 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Insider Activity

In related news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.28% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zimmer Biomet

Several institutional investors have recently made changes to their positions in ZBH. DV Equities LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at about $25,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet during the fourth quarter worth about $30,000. Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet during the fourth quarter worth about $31,000. Flagship Harbor Advisors LLC acquired a new position in Zimmer Biomet during the fourth quarter worth about $32,000. Finally, Elevation Wealth Partners LLC grew its position in Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 229 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.